Abstract
Chemotherapy-induced anemia is the predominant adverse event observed in individuals undergoing cancer treatment, resulting in a reduction in red blood cells and hemoglobin levels. This condition manifests through indicators such as diminished quality of life and fatigue. Effective approaches for managing recurrent chemotherapy-induced anemia encompass the use of erythropoietin-stimulating agents, blood transfusions, and intravenous iron supplementation. Each of these interventions presents distinct pros and cons, with selecting a particular treatment modality contingent upon the severity of anemia and the duration of malignancy. A comprehensive review of scholarly literature reveals a high prevalence of anemia among cancer patients receiving chemotherapy. Ongoing research endeavors are focused on developing pharmacological agents for cancer treatment that are devoid of adverse effects, particularly concerning anemia, a common complication associated with this therapeutic approach.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
